Thread by @kidney_boy

Here for the Late-Breaking Abstracts #NKFClinicals

The line-up #NKFClinicals
Matt Weir, Ajay Singh, and Glenn Chertow. All-star line up.

First up Matt Weir for the CKD outcomes in the DIAMOND Trial #NKFClinicals

RAASi are underutilized and underdosed in heart failure. Can potassium binders help with that? #NKFClinicals

We underuse and underdose because of hyperkalemia. This data represents the best case story and still one in four develop hyperkalemia. #NKFClinicals

The US Sucks at prescribing RAASi in CKD #NKFClinicals

No clinical studies show the utility of dietary management of hyperkalemia. #NKFClinicals

Patiromer is a calcium potassium exchange binders.
DIAMOND Trial is a CV outcome clinical trial to see if potassium mitigation moves the needle on CV events.

Enrolled people with hyperkalemia, then run-in with everyone on patiromer and then change half to placebo. But COVID got in the way and they had to knock down to a more modest outcomes. This study became underpowered to show reduced events. #FuckCovid #NKFClinicals

Table 1. People were on high doses of RAASi and MRA #NKFClinicals

Less hyperkalemia with the binder, no difference in events. #NKFClinicals

Pre-specified subgroup analysis of patients with GFR < 60 #NKFClinicals

Conclusion slide #NKFClinicals